PMA REORGANIZATION AND FUNCTION COMMITTEE
PMA REORGANIZATION AND FUNCTION COMMITTEE has been formed to determine "what, if any, changes should be made in the organization and mission of PMA to ensure that it serves our industry effectively," Pharmaceutical Manufacturers Association Chairman William Steere (Pfizer) announced Oct. 7. The ad hoc committee was formed by the PMA board "to examine the mission, structure and functions of the PMA to ensure that the association is properly organized to deal with sweeping changes in the pharmaceutical industry's public policy and market environments," PMA explained. The committee plans to report to the PMA board during the association's annual meeting in May 1994. PMA has retained the New York consulting firm McKinsey & Company "to assist with the study," PMA said. "The committee and McKinsey will work closely with PMA President Gerald Mossinghoff and the PMA senior staff," Steere said. He cited the increased influence of managed care, greater generic drug penetration and the proposal to expand drug coverage to all Americans as "revolutionary changes" facing the industry. The committee will be chaired by Searle Chairman and PMA Chairman-elect Sheldon Gilgore, NM. Members include Schering- Plough President Richard Kogan, Genentech CEO Kirk Raab, Glaxo Inc. Chairman and CEO Charles Sanders and Warner-Lambert President Lodewijk de Vink. Retired Hoffmann-La Roche Chairman Irwin Lerner will be a consultant to the committee, PMA said. On Oct. 8, PMA announced the resignation of VP-Association Relations Richard Stone. He is taking a position outside PMA, the association said. No replacement has been named.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth